BLA 761150 · Tersera Therapeutics LLC
Margenza
Margetuximab-Cmkb · Injection · HER2/neu Receptor Antagonist
NovelLast checked: Nov 20, 2026Latest source record: Jan 15, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Dec 16, 2020
Approved uses
2
Original approval plus efficacy supplements
Registered trials
11
2 Phase 3, 1 recruiting
FAERS reports
27
14 serious, 9 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: LEFT VENTRICULAR DYSFUNCTION AND EMBRYO-FETAL TOXICITY WARNING: LEFT VENTRICULAR DYSFUNCTION AND EMBRYO-FETAL TOXICITY See full prescribing information for complete boxed warning. Left Ventricular Dysfunction: MARGENZA may lead to reductions in left ventricular ejection fraction (LVEF). Evaluate cardiac function prior to and during treatment. Discontinue MARGENZA treatment for a confirmed clinically significant decrease in left ventricular function. ( 2.2 , 5.1 , 6.1 ) Embryo-Fetal Toxicity: Exposure to MARGENZA during pregnancy can cause embryo-fetal harm. Advise patients of the risk and need for effective contraception. ( 5.2 , 8.1 , 8.3 ) Left Ventricular Dysfunction: MARGENZA may lead to reductions in left ventricular ejection fraction (LVEF). Evaluate cardiac function prior to and during treatment. Discontinue MARGENZA treatment for a confirmed clinically significant...
What it is approved for
From the label in effect Feb 11, 2025.
MARGENZA is indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease [see Dosage and Administration (2.1) and Clinical Studies (14.1) ]. MARGENZA is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. ( 1 , 2.1 , 14.1 )
Mechanism: Margetuximab-cmkb binds to the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2). Upon binding to HER2-expressing tumor cells, margetuximab-cmkb inhibits tumor cell proliferation, reduces shedding of the HER2 extracellular domain and mediates antibody-dependent cellular cytotoxicity (ADCC). In vitro, the modified Fc region of margetuximab-cmkb increases binding to activating Fc receptor FCGR3A (CD16A) and decreases binding to inhibitory Fc receptor FCGR2B (CD32B). These changes lead to greater in vitro ADCC and NK cell activation.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 25, 2023 Supplement 5 · Efficacy LetterLabel
- Dec 16, 2020 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
- MARGENZA · MARGETUXIMAB-CMKB 250MG/10ML(25MG/ML) · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Margetuximab" as an intervention, any sponsor and status, largest first.
- Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast CancerPivotal-lookingCompleted
MacroGenicsIndustry
NCT02492711 · 624 participants · Start Aug 24, 2015 · Primary completion Aug 11, 2021
Drug: Margetuximab; Trastuzumab and 1 more · For: HER-2 Positive Breast Cancer; Metastatic Neoplasm
Sites: Chandler, Arizona; Gilbert, Arizona; Goodyear, Arizona · 167 sites in all
MacroGenicsIndustry
NCT03219268 · 277 participants · Start Aug 18, 2017 · Primary completion Feb 8, 2023
Drug: tebotelimab 1 mg; tebotelimab 3 mg and 9 more · For: Advanced Solid Tumors; Hematologic Neoplasms; Ovarian Cancer and 7 more
Sites: Gilbert, Arizona; Los Angeles, California; Newport Beach, California · 40 sites in all
- MARGetuximab Or Trastuzumab (MARGOT)Pivotal-lookingActive, not recruiting
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT04425018 · 174 participants · Start Jul 13, 2020 · Primary completion Oct 24, 2024
Drug: Paclitaxel; Pertuzumab and 2 more · For: Breast Cancer; Stage II Breast Cancer; Stage III Breast Cancer and 1 more
Sites: Washington D.C., District of Columbia; Boston, Massachusetts; Foxborough, Massachusetts · 14 sites in all
- A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBCPivotal-lookingStatus unknown
Zai Lab (Shanghai) Co., Ltd.Industry
NCT04262804 · 123 participants · Start Jan 13, 2020 · Primary completion Sep 3, 2021
Drug: Margetuximab; Trastuzumab and 3 more · For: Breast Cancer Metastatic
Sites: Taipei, Taiwan
MacroGenicsIndustry
NCT02689284 · 95 participants · Start Jan 2016 · Primary completion Jan 2021
Drug: Margetuximab 10 mg/kg; Margetuximab 15 mg and 1 more · For: Gastric Cancer; Stomach Cancer; Esophageal Cancer
Sites: New Haven, Connecticut; Washington D.C., District of Columbia; Chicago, Illinois · 28 sites in all
- Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerPivotal-lookingCompleted
MacroGenicsIndustry
NCT04082364 · 82 participants · Start Sep 30, 2019 · Primary completion Jan 15, 2024
Drug: margetuximab; Retifanlimab and 2 more · For: Gastric Cancer; Gastroesophageal Junction Cancer; HER2-positive Gastric Cancer
Sites: Scottsdale, Arizona; Duarte, California; Los Angeles, California · 73 sites in all
MacroGenicsIndustry
NCT01148849 · 66 participants · Start Jul 2010 · Primary completion Jun 14, 2022
Drug: margetuximab · For: Breast Cancer; Gastric Cancer
Sites: Bethesda, Maryland; Nashville, Tennessee; Seoul, South Korea
- Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted TherapyRecruiting
Vanderbilt-Ingram Cancer CenterAcademic, hospital or other
NCT06828588 · 30 participants (planned) · Start Apr 16, 2026 · Primary completion Dec 2027
Drug: [68Ga]Ga-ABY-025 · For: Locally Advanced Cancer; Metastatic Cancer; HER2 and 2 more
Sites: Nashville, Tennessee
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death5
- disease progression5
- chills3
- infusion related reaction2
- abdominal pain1
- alopecia1
- anaphylactic reaction1
- asthenia1
- blood pressure decreased1
- cardiac disorder1
- constipation1
- diarrhoea1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 8 |
| 2022 | 12 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Margenza (Margetuximab-Cmkb) · HCPCS J9353
2024 spending
$5.3M
Beneficiaries
110
520 claims
Per beneficiary
$47,995
2024 ASP limit $47.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $2,339,272 |
| 2022 | $5,879,953 |
| 2023 | $5,363,231 |
| 2024 | $5,279,486 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.
Rugo HS, Im SA, Cardoso F, et al. · JAMA Oncol 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer.
Royce M, Osgood CL, Amatya AK, et al. · Clin Cancer Res 2022 · Multicenter Study, Randomized Controlled Trial
- MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.
Catenacci DV, Rosales M, Chung HC, et al. · Future Oncol 2021 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update.
Giordano SH, Franzoi MAB, Temin S, et al. · J Clin Oncol 2022 · Systematic Review
- The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.
Luke JJ, Patel MR, Blumenschein GR, et al. · Nat Med 2023 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
Rugo HS, Im SA, Cardoso F, et al. · J Clin Oncol 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Tersera Therapeutics LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.